Good evening. This snapshot of stories and roundup is recommended just for you, based on your interests and reading history.

The Food and Drug Administration “must keep their eye on the science, data, and patient safety as they consider their options and next steps,” says Ilisa Bernstein, a former deputy director of the agency's drug compliance office. (Sarah Silbiger/Getty Images)

Why controversial products claiming to help insomnia and migraines just got a big boost

 What to know

An FDA panel recommended loosening regulations on six peptide treatments despite lacking rigorous clinical trials, a move supported by some physicians and celebrities. The FDA will decide if compounding pharmacies can produce these peptides, which are currently sold online with potential impurities. The decision could impact the pharmacy industry significantly.

Summary is AI-generated, newsroom-reviewed.

Join the conversation

Have a question? Ask the Post AI to learn more